Racial differences in the systemic inflammatory response to prostate cancer

Systemic inflammation may increase risk for prostate cancer progression, but the role it plays in prostate cancer susceptibility is unknown. From a cohort of over 10,000 men who had either a prostate biopsy or transurethral resection that yielded a benign finding, we analyzed 517 incident prostate cancer cases identified during follow-up and 373 controls with one or more white blood cell tests during a follow-up period between one and 18 years. Multilevel, multivariable longitudinal models were fit to two measures of systemic inflammation, neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR), to determine NLR and MLR trajectories associated with increased risk for prostate cancer. For both measures, we found no significant differences in the trajectories by case/control status, however in modeling NLR trajectories there was a significant interaction between race (white or Black and case-control status. In race specific models, NLR and MLR values were consistently higher over time among white controls than white cases while case-control differences in NLR and MLR trajectories were not apparent among Black men. When cases were classified as aggressive as compared to non-aggressive, the case-control differences in NLR and MLR values over time among white men were most apparent for non-aggressive cases. For NLR among white men, significant case-control differences were observed for the entire duration of observation for men who had inflammation in their initial prostate specimen. It is possible that, among white men, monitoring of NLR and MLR trajectories after an initial negative biopsy may be useful in monitoring prostate cancer risk.

[1]  E. Giovannucci,et al.  Inflammatory serum markers and risk and severity of prostate cancer: The PROCA‐life study , 2020, International journal of cancer.

[2]  M. Shaul,et al.  Tumour-associated neutrophils in patients with cancer , 2019, Nature Reviews Clinical Oncology.

[3]  K. Egan,et al.  Sociodemographic and lifestyle factors associated with the neutrophil-to-lymphocyte ratio. , 2019, Annals of epidemiology.

[4]  L. Dennis,et al.  A Systematic Review and Meta-analysis of Associations between Clinical Prostatitis and Prostate Cancer: New Estimates Accounting for Detection Bias , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[5]  S. M. Warli,et al.  Systemic Inflammatory Response in Predicting Prostate Cancer: The Diagnostic Value of Neutrophil-To-Lymphocyte Ratio , 2019, Open access Macedonian journal of medical sciences.

[6]  Hao Peng,et al.  Prognostic significance of elevated pretreatment systemic inflammatory markers for patients with prostate cancer: a meta-analysis , 2019, Cancer Cell International.

[7]  S. Avcı,et al.  Lymphocyte-to-monocyte ratio is a valuable marker to predict prostate cancer in patients with prostate specific antigen between 4 and 10 ng/dl. , 2019, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[8]  V. Mirone,et al.  Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients , 2018, Urologia Internationalis.

[9]  M. Terris,et al.  Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database , 2018, Cancer Causes & Control.

[10]  M. Abolhasani,et al.  The role of blood neutrophil count and the neutrophil-to-lymphocyte ratio as a predictive factor for prostate biopsy results , 2018, Urologia.

[11]  L. Ying,et al.  Prognostic Significance of Pre-Operative Monocyte-to-Lymphocyte Ratio in Lung Cancer Patients Undergoing Radical Surgery , 2018, Laboratory medicine.

[12]  Yanqing Wang,et al.  Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients , 2018, The Prostate.

[13]  D. Moreira,et al.  Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta‐Analysis , 2017, The Journal of urology.

[14]  E. Monti,et al.  The association between prostatitis and prostate cancer. Systematic review and meta-analysis. , 2017, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[15]  E. Morii,et al.  Peripheral blood monocyte count reflecting tumor‐infiltrating macrophages is a predictive factor of adverse pathology in radical prostatectomy specimens , 2017, The Prostate.

[16]  Yingwei Xue,et al.  Monocyte to lymphocyte ratio predicts survival in patients with advanced gastric cancer undergoing neoadjuvant chemotherapy , 2017, OncoTargets and therapy.

[17]  I. Thompson,et al.  A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[18]  O. Bischof,et al.  Cytokine-induced senescence for cancer surveillance , 2017, Cancer and Metastasis Reviews.

[19]  X. Wan,et al.  Preoperative Monocyte-to-Lymphocyte Ratio in Peripheral Blood Predicts Stages, Metastasis, and Histological Grades in Patients with Ovarian Cancer12 , 2016, Translational oncology.

[20]  K. Ru,et al.  Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma , 2016, Oncotarget.

[21]  N. Nonomura,et al.  Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer , 2016, Oncotarget.

[22]  H. Feigelson,et al.  Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis , 2017, Cancer Causes & Control.

[23]  G. Oates,et al.  Systemic Inflammation in Midlife: Race, Socioeconomic Status, and Perceived Discrimination. , 2017, American journal of preventive medicine.

[24]  A. Sciarra,et al.  Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review , 2016, Journal of Inflammation.

[25]  P. Tassone,et al.  Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse , 2016, Cancer biology & therapy.

[26]  Xintao Li,et al.  Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis , 2016, PloS one.

[27]  X. Gu,et al.  Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients , 2016, Scientific Reports.

[28]  Neil Pearce,et al.  Analysis of matched case-control studies , 2016, British Medical Journal.

[29]  Yi Xiao,et al.  Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer , 2016, Medicine.

[30]  A. Rundle,et al.  Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer , 2016 .

[31]  J. Oh,et al.  Association of the neutrophil-to-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy , 2015, Asian journal of andrology.

[32]  N. Hamidi,et al.  Evaluation of neutrophil-to-lymphocyte ratio prior to prostate biopsy to predict biopsy histology: Results of 1836 patients. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[33]  D. Taussky,et al.  Neutrophil count is associated with survival in localized prostate cancer , 2015, BMC Cancer.

[34]  T. Yamanaka,et al.  Neutrophil-to-lymphocyte ratio predicts prostatic carcinoma in men undergoing needle biopsy , 2015, Oncotarget.

[35]  J. Meeker,et al.  Statistical methods for modeling repeated measures of maternal environmental exposure biomarkers during pregnancy in association with preterm birth , 2015, Environmental Health.

[36]  K. Ceylan,et al.  Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio. , 2015, Cancer biomarkers : section A of Disease markers.

[37]  E. Taioli,et al.  Average Values and Racial Differences of Neutrophil Lymphocyte Ratio among a Nationally Representative Sample of United States Subjects , 2014, PloS one.

[38]  S. Albayrak,et al.  Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? , 2014, Asian Pacific journal of cancer prevention : APJCP.

[39]  N. Nonomura,et al.  White blood cell count is positively associated with benign prostatic hyperplasia , 2014, International journal of urology : official journal of the Japanese Urological Association.

[40]  G. Andriole,et al.  Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study , 2014, Cancer.

[41]  A. D. De Marzo,et al.  The role of inflammation in prostate cancer. , 2014, Advances in experimental medicine and biology.

[42]  Junjian Liu,et al.  The Role of Prostatitis in Prostate Cancer: Meta-Analysis , 2013, PloS one.

[43]  K. Ronkainen,et al.  Prediagnostic circulating markers of inflammation and risk of prostate cancer , 2013, International journal of cancer.

[44]  T. Tammela,et al.  Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate‐specific antigen (PSA) concentration in the Finnish prostate cancer screening trial , 2013, BJU international.

[45]  S. Clarke,et al.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. , 2013, Critical reviews in oncology/hematology.

[46]  Deepa Naishadham,et al.  Cancer statistics for African Americans, 2013 , 2013, CA: a cancer journal for clinicians.

[47]  Aliccia Bollig-Fischer,et al.  Genes Associated with Prostate Cancer Are Differentially Expressed in African American and European American Men , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[48]  Jennifer R. Rider,et al.  CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3+ regulatory T cells with respect to lethal prostate cancer , 2013, Modern Pathology.

[49]  K. Beullens,et al.  Results From a Prospective Cohort Study , 2013 .

[50]  Jennifer G. Robinson,et al.  Genome-wide association and population genetic analysis of C-reactive protein in African American and Hispanic American women. , 2012, American journal of human genetics.

[51]  K. Fujita,et al.  Low serum neutrophil count predicts a positive prostate biopsy , 2012, Prostate Cancer and Prostatic Diseases.

[52]  S. Albelda,et al.  Tumor-associated neutrophils: friend or foe? , 2012, Carcinogenesis.

[53]  A. Rundle,et al.  Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer , 2012, Modern Pathology.

[54]  G. D. de Bock,et al.  The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis , 2011, British Journal of Cancer.

[55]  H. Markus,et al.  Population differences in proinflammatory biology: Japanese have healthier profiles than Americans , 2011, Brain, Behavior, and Immunity.

[56]  A. Sica Role of tumour-associated macrophages in cancer-related inflammation. , 2010, Experimental oncology.

[57]  W. Gerald,et al.  Copy number and gene expression differences between African American and Caucasian American prostate cancer , 2010, Journal of Translational Medicine.

[58]  J. Witte,et al.  Prostatitis, Sexually Transmitted Diseases, and Prostate Cancer: The California Men's Health Study , 2007, PloS one.

[59]  Brady T. West,et al.  Analyzing Longitudinal Data With the Linear Mixed Models Procedure in SPSS , 2009, Evaluation & the health professions.

[60]  Robyn L Prueitt,et al.  Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.

[61]  L. Bégin,et al.  Chronic inflammation is negatively associated with prostate cancer and high‐grade prostatic intraepithelial neoplasia on needle biopsy , 2007, International journal of clinical practice.

[62]  John T. Wei,et al.  Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. , 2006, The Journal of urology.

[63]  T. Erlinger,et al.  C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. , 2006, European journal of cancer.

[64]  Paolo Vineis,et al.  Design Options for Molecular Epidemiology Research within Cohort Studies , 2005, Cancer Epidemiology Biomarkers & Prevention.

[65]  L. Dennis,et al.  Epidemiologic association between prostatitis and prostate cancer. , 2002, Urology.

[66]  Judith D. Singer,et al.  Using SAS PROC MIXED to Fit Multilevel Models, Hierarchical Models, and Individual Growth Models , 1998 .

[67]  J. Eastham,et al.  Clinical Characteristics and Biopsy Specimen Features in African-American and White Men Without Prostate Cancer , 1998 .

[68]  S. Thompson Advances in experimental medicine and biology , 1996 .